Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM). MCAD prevents toxic lipid buildup, in addition to its normal role in energy production, so targeting MCAD causes irreversible damage and cell death specifically in cancer cells.
The study was published today in Cancer Discovery, a journal of...
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for...
MD Anderson and other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
The University of Texas MD Anderson Cancer Center has united with fellow National Cancer Institute (NCI)-Designated Cancer Centers and partner...
New AI-based tool can find rare cell populations in large single-cell datasets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind artificial intelligence (AI)-based tool that can accurately identify rare groups of biologically important cells from single-cell datasets, which often contain gene or protein expression data from thousands of cells. The research was published today in Nature Computational Science.
This computational tool, called SCMER (Single-Cell...
CPRIT renews funding for MD Anderson training program focused on education and research
Today, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded The University of Texas MD Anderson Cancer Center $4 million...
Combination therapy achieves high rates of response for patients with acute lymphoblastic leukemia
ABSTRACT #7001
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed...
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
ABSTRACT #3001
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center...
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new...
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody...
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death...
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational...
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer...